McAnally L E, Corn C R, Hamilton S F
College of Pharmacy, Department of Pharmacy Practice, University of Oklahoma, Health Sciences Center, Oklahoma City 73190.
Ann Pharmacother. 1992 Dec;26(12):1530-4. doi: 10.1177/106002809202601210.
To review current information relevant to the use of aspirin for preventing vascular death in women, and to provide recommendations based on this information.
References from pertinent articles are identified throughout the text.
Based on current information, low-dose aspirin is not recommended as primary prevention for cardiovascular death in women; efforts are better focused at promoting risk-factor reduction. Low-dose aspirin is recommended for reducing further cardiovascular morbidity and mortality in women with known cardiovascular disease. Women presenting with unstable angina or myocardial infarction should receive aspirin 325 mg as soon as the diagnosis is confirmed, and this dosage should be continued on a chronic basis. Women who have experienced transient ischemic attacks or ischemic stroke should receive aspirin 1000 mg/d, with a subsequent dosage reduction to 325 mg/d in patients who do not tolerate the higher dose.
Current recommendations are based on the results of studies that involved few women. Further investigation of antiplatelet agents for primary and secondary prevention of vascular death in women is needed.
回顾与阿司匹林用于预防女性血管性死亡相关的现有信息，并基于此信息提供建议。
文中各处均列出了相关文章的参考文献。
基于现有信息，不推荐将低剂量阿司匹林作为女性心血管死亡的一级预防措施；更好的做法是将精力集中在促进降低危险因素上。对于已知患有心血管疾病的女性，推荐使用低剂量阿司匹林以降低进一步的心血管发病率和死亡率。出现不稳定型心绞痛或心肌梗死的女性，一旦确诊应立即服用325毫克阿司匹林，且该剂量应长期维持。经历过短暂性脑缺血发作或缺血性中风的女性应服用1000毫克/天的阿司匹林，对于不能耐受较高剂量的患者，随后剂量应减至325毫克/天。
当前的建议基于涉及女性较少的研究结果。需要进一步研究抗血小板药物用于女性血管性死亡的一级和二级预防。
